Etesian Wealth Advisors Inc. Lowers Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Etesian Wealth Advisors Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,568 shares of the biopharmaceutical company’s stock after selling 1,629 shares during the quarter. Etesian Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $1,305,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in GILD. Manning & Napier Advisors LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at approximately $25,328,000. Legal & General Group Plc raised its position in shares of Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Gilead Sciences during the 1st quarter worth approximately $462,000. Brookstone Capital Management raised its position in shares of Gilead Sciences by 751.1% during the 1st quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company’s stock worth $9,322,000 after purchasing an additional 112,305 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after purchasing an additional 33,162 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 36,847 shares of company stock valued at $3,033,340. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 0.7 %

Shares of NASDAQ GILD traded down $0.64 during trading on Friday, hitting $86.72. 4,365,082 shares of the company traded hands, compared to its average volume of 7,080,318. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The company has a 50-day moving average price of $81.06 and a 200-day moving average price of $72.80. The firm has a market capitalization of $108.04 billion, a P/E ratio of 240.89, a P/E/G ratio of 2.98 and a beta of 0.18. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $6.95 billion during the quarter, compared to analysts’ expectations of $6.64 billion. On average, equities analysts predict that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.55%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Piper Sandler restated an “overweight” rating and set a $95.00 price objective on shares of Gilead Sciences in a research report on Wednesday, September 11th. Cantor Fitzgerald restated a “neutral” rating and set a $70.00 price objective on shares of Gilead Sciences in a research report on Monday, September 16th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Wells Fargo & Company upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $78.00 to $100.00 in a research report on Monday, October 7th. Finally, Sanford C. Bernstein started coverage on Gilead Sciences in a research report on Thursday. They set an “outperform” rating and a $105.00 price objective for the company. Ten research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.37.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.